Počet záznamů: 1  

NOVEL PSMA-SPECIFIC BINDING PROTEINS

  1. 1.
    0563670 - BTÚ 2023 RIV eng P - Patentový dokument
    Skerra, A. - Richter, A. - Völker, M. - Bařinka, Cyril - Ptáček, Jakub
    NOVEL PSMA-SPECIFIC BINDING PROTEINS.
    2022. Vlastník: Biotechnologický ústav AV ČR, v. v. i., Technische Universitaet Muenchen. Datum udělení patentu: 11.10.2022. Číslo patentu: US 11464877
    Institucionální podpora: RVO:86652036
    Klíčová slova: Prostate-specific membrane antigen * Anticalin * protein engineering
    Obor OECD: Biochemistry and molecular biology
    https://worldwide.espacenet.com/patent/search/family/053540662/publication/WO2017005799A1?q=PCT%2FEP2016%2F065993

    The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention. In addition, the present invention relates to a pharmaceutical or diagnostic composition to the PSMA-specific binding protein of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the PSMA-specific binding protein produced by the method of the invention, for use in therapy and/or diagnosis, and in particular for use in the therapy and/or diagnosis of tumors, Crohn's disease and/or neurological diseases.
    Trvalý link: https://hdl.handle.net/11104/0335559

     
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.